Avoro News

Avoro Capital Updates

We are pleased to share industry insights and updates on Avoro and our portfolio companies. Please reach out if you would like to learn more.

Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers

CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ — Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Management, and additional new investors …

Read More

Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines

Molecular engineering company’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease March 31, 2021 10:00 AM Eastern Daylight Time ALAMEDA, Calif.–(BUSINESS WIRE)–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed …

Read More

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

March 12, 2021 07:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and …

Read More

Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

Proceeds to support advancement of the company’s unique discovery platform and robust portfolio of programs focused on high value, traditionally undruggable targets February 24, 2021 08:00 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers …

Read More

Avoro Ventures Adds Sara Nayeem, MD, as a Partner

February 18, 2021 08:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Avoro Ventures announced today that Sara Nayeem, MD, has joined the firm as a Partner, focused on its venture capital investment efforts. Dr. Nayeem joins Avoro Ventures after 12 years with New Enterprise Associates, Inc. (NEA), where she was a Partner in the firm’s biopharma …

Read More

LATEST
202120202018201720152014